Liver Disease Clinical Trials

Showing 421-440 of 1,498 trials

Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal

NCT06707129

Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.

Non-alcoholic Fatty Liver Disease

Beijing Municipal Administration of Hospitals50 participantsStarted Aug 2024

Beijing, Beijing Municipality, China

COMPLETEDEARLY Phase 1

A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

NCT05720702

The purpose of the study is to assess the feasibility of a trial to test the effects of homocysteine (Hcy) lowering supplements in patients with NAFLD. NAFLD patients will be asked to take Hcy lowering supplements (Vitamin B12, Folate, Vitamin B6, and Betaine) daily for 12 weeks. Over the course of approximately 12 to 13 weeks, participants will complete two in person visits and two phone visits to complete activities such as physical exam, fibroscan, blood draws, and questionnaires.

NAFLD

Duke University31 participantsStarted Jun 2023

Durham, North Carolina, United States

RECRUITINGNA

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

NCT06704321

This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota among both men and women with MASLD.

Non-Alcoholic Fatty Liver Disease

Valbiotis70 participantsStarted Jan 2024

Québec, Quebec, Canada

Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal

A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

Related Searches

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Liver Fibrosis Assessment in Diabetic Patients

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Tocotrienol as a Treatment for Non-alcoholic Fatty Liver Disease

Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension

TIPS Plus Transvenous Obliteration for Gastric Varices

Impact of Live Streaming Exercise on Liver Health in MASLD Pregnant Women

Role of ALBI Score and Sarcopenia As Prognostic Predictors Among Hospitalized Cirrhotic Patients with Hepatic Encephalopathy

Early Ascitis Parencentesis in SBP

Genetic Variants Associated With the Risk of Gall Stones and Cirrhosis.

New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

Intermittent Fasting Versus Diet to Stop Hypertension on Metabolic Risk Profile in Nonalcoholic Fatty Liver Patients

Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.

Genetic-specific Effects of Fructose on Liver Lipogenesis

Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease

Smart Watch Insights for Prevention of Exacerbations and Enhance Rehabilitation - Movement Study

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)